Stem definition | Drug id | CAS RN |
---|---|---|
vinca alkaloids | 2823 | 865-21-4 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 28 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.14 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 67 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 5, 1965 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Neutropenia | 185.67 | 27.32 | 135 | 4685 | 147830 | 50452474 |
Febrile neutropenia | 150.05 | 27.32 | 101 | 4719 | 97566 | 50502738 |
Pulmonary toxicity | 112.33 | 27.32 | 35 | 4785 | 5527 | 50594777 |
Pancytopenia | 88.03 | 27.32 | 69 | 4751 | 83961 | 50516343 |
Malignant neoplasm progression | 71.44 | 27.32 | 56 | 4764 | 68068 | 50532236 |
Tissue infiltration | 64.23 | 27.32 | 14 | 4806 | 539 | 50599765 |
Second primary malignancy | 63.01 | 27.32 | 24 | 4796 | 6890 | 50593414 |
Basal ganglion degeneration | 62.62 | 27.32 | 13 | 4807 | 395 | 50599909 |
Product use in unapproved indication | 61.62 | 27.32 | 65 | 4755 | 115754 | 50484550 |
Uterine enlargement | 55.09 | 27.32 | 14 | 4806 | 1052 | 50599252 |
Disease progression | 51.32 | 27.32 | 54 | 4766 | 95812 | 50504492 |
Febrile bone marrow aplasia | 50.74 | 27.32 | 20 | 4800 | 6291 | 50594013 |
Myelodysplastic syndrome | 50.71 | 27.32 | 26 | 4794 | 15106 | 50585198 |
Inguinal hernia | 48.57 | 27.32 | 14 | 4806 | 1692 | 50598612 |
Interstitial lung disease | 47.85 | 27.32 | 40 | 4780 | 53136 | 50547168 |
Anaesthesia | 46.80 | 27.32 | 10 | 4810 | 350 | 50599954 |
Toxic neuropathy | 46.21 | 27.32 | 10 | 4810 | 372 | 50599932 |
Refractory anaemia with an excess of blasts | 45.53 | 27.32 | 10 | 4810 | 399 | 50599905 |
Psychogenic seizure | 45.09 | 27.32 | 13 | 4807 | 1572 | 50598732 |
Ileus | 42.22 | 27.32 | 22 | 4798 | 13207 | 50587097 |
Dysaesthesia | 41.50 | 27.32 | 15 | 4805 | 3720 | 50596584 |
Neurological decompensation | 40.49 | 27.32 | 13 | 4807 | 2257 | 50598047 |
Hypochromic anaemia | 39.87 | 27.32 | 12 | 4808 | 1684 | 50598620 |
Congestive cardiomyopathy | 39.20 | 27.32 | 16 | 4804 | 5502 | 50594802 |
Off label use | 39.08 | 27.32 | 116 | 4704 | 474310 | 50125994 |
Premature menopause | 38.98 | 27.32 | 10 | 4810 | 780 | 50599524 |
Premature baby | 38.08 | 27.32 | 23 | 4797 | 18314 | 50581990 |
Monoplegia | 37.89 | 27.32 | 13 | 4807 | 2770 | 50597534 |
Pyrexia | 37.19 | 27.32 | 99 | 4721 | 380104 | 50220200 |
Acute myeloid leukaemia | 36.82 | 27.32 | 21 | 4799 | 15053 | 50585251 |
Hyperpyrexia | 36.73 | 27.32 | 13 | 4807 | 3036 | 50597268 |
Pneumocystis jirovecii pneumonia | 34.67 | 27.32 | 20 | 4800 | 14643 | 50585661 |
Pleuroparenchymal fibroelastosis | 33.67 | 27.32 | 5 | 4815 | 18 | 50600286 |
Foetal exposure during pregnancy | 31.94 | 27.32 | 24 | 4796 | 27335 | 50572969 |
Mucosal inflammation | 31.63 | 27.32 | 28 | 4792 | 40114 | 50560190 |
Lung disorder | 30.91 | 27.32 | 29 | 4791 | 44770 | 50555534 |
Pericarditis constrictive | 30.35 | 27.32 | 7 | 4813 | 349 | 50599955 |
Meningitis streptococcal | 30.10 | 27.32 | 6 | 4814 | 148 | 50600156 |
Pseudohyponatraemia | 30.10 | 27.32 | 5 | 4815 | 42 | 50600262 |
Lymphadenopathy | 29.71 | 27.32 | 25 | 4795 | 33474 | 50566830 |
Klebsiella infection | 28.94 | 27.32 | 14 | 4806 | 7180 | 50593124 |
Intervertebral disc disorder | 28.79 | 27.32 | 12 | 4808 | 4348 | 50595956 |
Splenomegaly | 27.81 | 27.32 | 15 | 4805 | 9645 | 50590659 |
Leukaemia | 27.81 | 27.32 | 11 | 4809 | 3488 | 50596816 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 215.02 | 26.53 | 169 | 5059 | 112071 | 29457228 |
Second primary malignancy | 169.14 | 26.53 | 58 | 5170 | 6647 | 29562652 |
Neutropenia | 123.22 | 26.53 | 133 | 5095 | 131578 | 29437721 |
Acute myeloid leukaemia | 103.81 | 26.53 | 53 | 5175 | 16460 | 29552839 |
Cardiotoxicity | 96.55 | 26.53 | 35 | 5193 | 4709 | 29564590 |
Product use in unapproved indication | 83.26 | 26.53 | 89 | 5139 | 86786 | 29482513 |
Off label use | 78.56 | 26.53 | 167 | 5061 | 300633 | 29268666 |
Azoospermia | 76.09 | 26.53 | 17 | 5211 | 388 | 29568911 |
Pulmonary toxicity | 70.32 | 26.53 | 28 | 5200 | 4862 | 29564437 |
Endocarditis noninfective | 69.64 | 26.53 | 13 | 5215 | 115 | 29569184 |
Neutrophil count decreased | 65.03 | 26.53 | 57 | 5171 | 43510 | 29525789 |
Chronic myeloid leukaemia | 61.16 | 26.53 | 20 | 5208 | 1974 | 29567325 |
Malignant neoplasm progression | 57.56 | 26.53 | 68 | 5160 | 73791 | 29495508 |
Cytomegalovirus chorioretinitis | 55.26 | 26.53 | 21 | 5207 | 3217 | 29566082 |
Testicular disorder | 54.67 | 26.53 | 14 | 5214 | 578 | 29568721 |
Myositis | 50.45 | 26.53 | 28 | 5200 | 10255 | 29559044 |
Autoimmune neutropenia | 48.70 | 26.53 | 11 | 5217 | 264 | 29569035 |
Interstitial lung disease | 48.05 | 26.53 | 55 | 5173 | 57663 | 29511636 |
Myelodysplastic syndrome | 45.46 | 26.53 | 32 | 5196 | 17762 | 29551537 |
Pneumocystis jirovecii pneumonia | 44.79 | 26.53 | 31 | 5197 | 16748 | 29552551 |
Bone marrow failure | 41.09 | 26.53 | 36 | 5192 | 27413 | 29541886 |
Cytopenia | 38.13 | 26.53 | 23 | 5205 | 9836 | 29559463 |
Polyneuropathy | 36.12 | 26.53 | 24 | 5204 | 12128 | 29557171 |
Cardiac dysfunction | 35.52 | 26.53 | 13 | 5215 | 1794 | 29567505 |
Pulmonary fibrosis | 32.94 | 26.53 | 25 | 5203 | 15557 | 29553742 |
Pneumonia salmonella | 32.56 | 26.53 | 6 | 5222 | 49 | 29569250 |
Myelosuppression | 31.25 | 26.53 | 22 | 5206 | 12205 | 29557094 |
Treatment failure | 30.37 | 26.53 | 35 | 5193 | 36904 | 29532395 |
Cryptococcal fungaemia | 29.42 | 26.53 | 6 | 5222 | 87 | 29569212 |
Ichthyosis | 28.75 | 26.53 | 6 | 5222 | 98 | 29569201 |
Pyrexia | 28.46 | 26.53 | 113 | 5115 | 287509 | 29281790 |
Spindle cell sarcoma | 27.19 | 26.53 | 6 | 5222 | 129 | 29569170 |
Lung disorder | 27.05 | 26.53 | 30 | 5198 | 30332 | 29538967 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 315.34 | 23.00 | 239 | 8882 | 187418 | 64302193 |
Neutropenia | 270.04 | 23.00 | 242 | 8879 | 239382 | 64250229 |
Second primary malignancy | 239.68 | 23.00 | 83 | 9038 | 12254 | 64477357 |
Pulmonary toxicity | 171.69 | 23.00 | 59 | 9062 | 8502 | 64481109 |
Acute myeloid leukaemia | 157.18 | 23.00 | 77 | 9044 | 27386 | 64462225 |
Product use in unapproved indication | 137.58 | 23.00 | 146 | 8975 | 176472 | 64313139 |
Malignant neoplasm progression | 132.59 | 23.00 | 117 | 9004 | 112754 | 64376857 |
Off label use | 91.57 | 23.00 | 244 | 8877 | 632562 | 63857049 |
Myelodysplastic syndrome | 89.33 | 23.00 | 53 | 9068 | 27526 | 64462085 |
Interstitial lung disease | 87.17 | 23.00 | 87 | 9034 | 97645 | 64391966 |
Pancytopenia | 85.10 | 23.00 | 103 | 9018 | 143206 | 64346405 |
Cardiotoxicity | 84.31 | 23.00 | 37 | 9084 | 10237 | 64479374 |
Chronic myeloid leukaemia | 82.48 | 23.00 | 27 | 9094 | 3347 | 64486264 |
Disease progression | 79.54 | 23.00 | 99 | 9022 | 141581 | 64348030 |
Neutrophil count decreased | 78.76 | 23.00 | 74 | 9047 | 77122 | 64412489 |
Pneumocystis jirovecii pneumonia | 73.91 | 23.00 | 47 | 9074 | 27587 | 64462024 |
Endocarditis noninfective | 66.60 | 23.00 | 13 | 9108 | 189 | 64489422 |
Myelitis | 64.39 | 23.00 | 20 | 9101 | 2094 | 64487517 |
Cytopenia | 58.79 | 23.00 | 33 | 9088 | 15438 | 64474173 |
Pyrexia | 56.42 | 23.00 | 190 | 8931 | 558454 | 63931157 |
Myelosuppression | 52.70 | 23.00 | 36 | 9085 | 23794 | 64465817 |
Lung disorder | 52.17 | 23.00 | 53 | 9068 | 60647 | 64428964 |
Tissue infiltration | 47.65 | 23.00 | 12 | 9109 | 581 | 64489030 |
Basal ganglion degeneration | 46.82 | 23.00 | 11 | 9110 | 397 | 64489214 |
Cytomegalovirus chorioretinitis | 44.58 | 23.00 | 19 | 9102 | 4893 | 64484718 |
Uterine enlargement | 44.38 | 23.00 | 12 | 9109 | 769 | 64488842 |
Myositis | 44.14 | 23.00 | 28 | 9093 | 16349 | 64473262 |
Mucosal inflammation | 43.80 | 23.00 | 49 | 9072 | 62535 | 64427076 |
Congestive cardiomyopathy | 41.86 | 23.00 | 23 | 9098 | 10321 | 64479290 |
Autoimmune neutropenia | 41.37 | 23.00 | 10 | 9111 | 408 | 64489203 |
Pleuroparenchymal fibroelastosis | 38.16 | 23.00 | 6 | 9115 | 21 | 64489590 |
Neuropathy peripheral | 36.36 | 23.00 | 62 | 9059 | 117463 | 64372148 |
Anaesthesia | 36.27 | 23.00 | 9 | 9112 | 410 | 64489201 |
Ileus | 35.60 | 23.00 | 28 | 9093 | 22938 | 64466673 |
Toxic neuropathy | 34.99 | 23.00 | 10 | 9111 | 786 | 64488825 |
Thrombocytopenia | 34.85 | 23.00 | 89 | 9032 | 223712 | 64265899 |
Polyneuropathy | 34.66 | 23.00 | 26 | 9095 | 19868 | 64469743 |
Refractory anaemia with an excess of blasts | 34.38 | 23.00 | 10 | 9111 | 836 | 64488775 |
Bone marrow failure | 34.33 | 23.00 | 38 | 9083 | 47914 | 64441697 |
Psychogenic seizure | 34.24 | 23.00 | 12 | 9109 | 1829 | 64487782 |
Pneumonia salmonella | 33.90 | 23.00 | 6 | 9115 | 49 | 64489562 |
Pulmonary fibrosis | 33.07 | 23.00 | 30 | 9091 | 29848 | 64459763 |
Febrile bone marrow aplasia | 32.23 | 23.00 | 20 | 9101 | 11235 | 64478376 |
Dysaesthesia | 31.55 | 23.00 | 15 | 9106 | 4980 | 64484631 |
Treatment failure | 31.46 | 23.00 | 58 | 9063 | 116758 | 64372853 |
Hypothyroidism | 28.85 | 23.00 | 32 | 9089 | 40425 | 64449186 |
Ichthyosis | 28.61 | 23.00 | 6 | 9115 | 127 | 64489484 |
Neoplasm progression | 28.52 | 23.00 | 32 | 9089 | 40932 | 64448679 |
Cryptococcal fungaemia | 27.25 | 23.00 | 6 | 9115 | 161 | 64489450 |
Peripheral sensory neuropathy | 27.09 | 23.00 | 18 | 9103 | 11360 | 64478251 |
Monoplegia | 26.95 | 23.00 | 12 | 9109 | 3431 | 64486180 |
Ileus paralytic | 26.78 | 23.00 | 16 | 9105 | 8399 | 64481212 |
Spindle cell sarcoma | 25.37 | 23.00 | 6 | 9115 | 223 | 64489388 |
Oropharyngeal squamous cell carcinoma | 24.68 | 23.00 | 6 | 9115 | 251 | 64489360 |
Hypochromic anaemia | 24.31 | 23.00 | 10 | 9111 | 2358 | 64487253 |
Neurological decompensation | 24.05 | 23.00 | 12 | 9109 | 4424 | 64485187 |
Splenic infection fungal | 23.84 | 23.00 | 5 | 9116 | 106 | 64489505 |
Lymphadenopathy | 23.58 | 23.00 | 31 | 9090 | 46655 | 64442956 |
Pneumonitis | 23.24 | 23.00 | 32 | 9089 | 50333 | 64439278 |
Lymphopenia | 23.12 | 23.00 | 23 | 9098 | 25634 | 64463977 |
None
Source | Code | Description |
---|---|---|
ATC | L01CA01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS Vinca alkaloids and analogues |
FDA CS | M0022674 | Vinca Alkaloids |
FDA EPC | N0000175612 | Vinca Alkaloid |
MeSH PA | D050256 | Antimitotic Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D000972 | Antineoplastic Agents, Phytogenic |
MeSH PA | D050257 | Tubulin Modulators |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Kaposi's sarcoma | indication | 109385007 | |
Hodgkin's disease | indication | 118599009 | |
Non-Hodgkin's lymphoma | indication | 118601006 | |
Langerhans cell histiocytosis, disseminated | indication | 118614007 | |
Mycosis fungoides | indication | 118618005 | |
Malignant tumor of testis | indication | 363449006 | DOID:2998 |
Carcinoma of female breast | indication | 447782002 | |
Gestational trophoblastic neoplasia | indication | 609519004 | DOID:3590 |
Metastatic Breast Carcinoma | indication | ||
Non-small cell lung cancer | off-label use | 254637007 | DOID:3908 |
Malignant tumor of head and/or neck | off-label use | 255056009 | |
Malignant tumor of urinary bladder | off-label use | 399326009 | DOID:11054 |
Neuroblastoma | off-label use | 432328008 | DOID:769 |
Ovarian Germ Cell Tumor Carcinoma | off-label use | ||
Mycosis | contraindication | 3218000 | DOID:1564 |
Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
Disorder of lung | contraindication | 19829001 | DOID:850 |
Viral disease | contraindication | 34014006 | DOID:934 |
Depressive disorder | contraindication | 35489007 | |
Hyperuricemia | contraindication | 35885006 | DOID:1920 |
Hepatic failure | contraindication | 59927004 | |
Bacterial infectious disease | contraindication | 87628006 | |
Impaired wound healing | contraindication | 271618001 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Peripheral nerve disease | contraindication | 302226006 | |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Protozoal Infection | contraindication | ||
Severe Leukopenia | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.32 | acidic |
pKa2 | 13.81 | acidic |
pKa3 | 7.54 | Basic |
pKa4 | 6.84 | Basic |
pKa5 | 6.11 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Tubulin beta | Tumour-associated antigen | INHIBITOR | IC50 | 9 | IUPHAR | SCIENTIFIC LITERATURE | |||
Canalicular multispecific organic anion transporter 1 | Transporter | WOMBAT-PK | |||||||
Multidrug resistance-associated protein 1 | Transporter | WOMBAT-PK | |||||||
Multidrug resistance-associated protein 7 | Transporter | WOMBAT-PK | |||||||
Multidrug resistance protein 1 | Transporter | Ki | 7 | CHEMBL | |||||
Thromboxane-A synthase | Enzyme | IC50 | 5.73 | DRUG MATRIX | |||||
Arachidonate 15-lipoxygenase | Enzyme | IC50 | 5.30 | DRUG MATRIX | |||||
Amine oxidase [flavin-containing] B | Enzyme | Ki | 4.11 | CHEMBL |
ID | Source |
---|---|
4019970 | VUID |
N0000148055 | NUI |
D01068 | KEGG_DRUG |
143-67-9 | SECONDARY_CAS_RN |
4017457 | VANDF |
4019970 | VANDF |
C0042670 | UMLSCUI |
CHEBI:27375 | CHEBI |
VLB | PDB_CHEM_ID |
CHEMBL159 | ChEMBL_ID |
CHEMBL508191 | ChEMBL_ID |
CHEMBL378544 | ChEMBL_ID |
D014747 | MESH_DESCRIPTOR_UI |
DB00570 | DRUGBANK_ID |
6851 | IUPHAR_LIGAND_ID |
1101 | INN_ID |
5V9KLZ54CY | UNII |
13342 | PUBCHEM_CID |
11198 | RXNORM |
5674 | MMSL |
7980 | MMSL |
856 | MMSL |
d00400 | MMSL |
002654 | NDDF |
002655 | NDDF |
12436009 | SNOMEDCT_US |
387051009 | SNOMEDCT_US |
387115000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Vinblastine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-278 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 12 sections |